Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance

Fujita E, Nagao Y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia. 1976;32(2):203-206.

Xu J, Wold EA, Ding Y, Shen Q, Zhou J. Therapeutic potential of oridonin and its analogs: from anticancer and antiinflammation to neuroprotection. Molecules. 2018;23(2),e474.

Ding Y, Ding C, Ye N, et al. Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem. 2016;122:102-117.

Han QB, Li ML, Li SH, Mou YK, Lin ZW, Sun HD. Ent-kaurane diterpenoids from isodon rubescens var. lushanensis. Chem Pharm Bull (Tokyo). 2003;51(7):790-793.

Liu QQ, Wang HL, Chen K, et al. Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B. J Dig Dis. 2016;17(2):104-112.

He H, Jiang H, Chen Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9(1),e2550.

Kadota S, Basnet P, Ishii E, Tamura T, Namba T. Antibacterial activity of trichorabdal a from Rabdosia trichocarpa against Helicobacter pylori. Zentralbl Bakteriol. 1997;286(1):63-67.

Kuo LM, Kuo CY, Lin CY, Hung MF, Shen JJ, Hwang TL. Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells. Molecules. 2014;19(3):3327-3344.

Bohanon FJ, Wang X, Ding C, et al. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J Surg Res. 2014;190(1):55-63.

Xu Y, Xue Y, Wang Y, Feng D, Lin S, Xu L. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharm. 2009;9(3):360-365.

Tan W, Lu J, Huang M, et al. Anti-cancer natural products isolated from Chinese medicinal herbs. Chin Med. 2011;6(1),e27.

Ma Z, Hu C, Zhang Y. Therapeutic effect of Rabdosia rubescens aqueous extract on chronic pharyngitis and its safety. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(2):170-173.

Li D, Han T, Xu S, et al. Antitumor and antibacterial derivatives of oridonin: a main composition of Dong-Ling-cao. Molecules. 2016;21(5):e575.

Zhou M, Yi Y, Hong L. Oridonin ameliorates lipopolysaccharide-induced endometritis in mice via inhibition of the TLR-4/NF-kappaB pathway. Inflammation. 2019;42(1):81-90.

Li J, Bao L, Zha D, et al. Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-kappaB signaling pathways. Int Immunopharm. 2018;55:9-19.

Huang W, Huang M, Ouyang H, Peng J, Liang J. Oridonin inhibits vascular inflammation by blocking NF-kappaB and MAPK activation. Eur J Pharmacol. 2018;826:133-139.

Zhao G, Zhang T, Ma X, et al. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget. 2017;8(40):68153-68164.

Deng Y, Chen C, Yu H, et al. Oridonin ameliorates lipopolysaccharide/D-galactosamine-induced acute liver injury in mice via inhibition of apoptosis. Am J Transl Res. 2017;9(9):4271-4279.

Zhao YJ, Lv H, Xu PB, et al. Protective effects of oridonin on the sepsis in mice. Kaohsiung J Med Sci. 2016;32(9):452-457.

Wang S, Zhang Y, Saas P, et al. Oridonin’s therapeutic effect: suppressing Th1/Th17 simultaneously in a mouse model of Crohn’s disease. J Gastroenterol Hepatol. 2015;30(3):504-512.

Wu QJ, Zheng XC, Wang T, Zhang TY. Effects of dietary supplementation with oridonin on the growth performance, relative organ weight, lymphocyte proliferation, and cytokine concentration in broiler chickens. BMC Vet Res. 2018;14(1):34.

Wu QJ, Zheng XC, Wang T, Zhang TY. Effects of oridonin on immune cells, Th1/Th2 balance and the expression of BLys in the spleens of broiler chickens challenged with Salmonella pullorum. Res Vet Sci. 2018;119:262-267.

Hu AP, Du JM, Li JY, Liu JW. Oridonin promotes CD4+/CD25+ Treg differentiation, modulates Th1/Th2 balance and induces HO-1 in rat splenic lymphocytes. Inflamm Res. 2008;57(4):163-170.

Wang J, Li F, Ding J, et al. Investigation of the antiasthmatic activity of Oridonin on a mouse model of asthma. Mol Med Rep. 2016;14(3):2000-2006.

Shang CH, Zhang QQ, Zhou JH. Oridonin inhibits cell proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like synoviocytes. Inflammation. 2016;39(2):873-880.

Zhou L, Sun L, Wu H, et al. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). Eur J Pharmacol. 2013;715(1–3):230-237.

Xie Z, Yu H, Sun X, et al. A novel diterpenoid suppresses osteoclastogenesis and promotes osteogenesis by inhibiting Ifrd1-mediated and IkappaBalpha-mediated p65 nuclear translocation. J Bone Miner Res. 2018;33(4):667-678.

Seo EJ, Fischer N, Efferth T. Phytochemicals as inhibitors of NF-kappaB for treatment of Alzheimer’s disease. Pharmacol Res. 2018;129:262-273.

Wang S, Yu L, Yang H, et al. Oridonin attenuates synaptic loss and cognitive deficits in an abeta1-42-induced mouse model of alzheimer’s disease. PloS One. 2016;11(3),e0151397.

Zhang ZY, Daniels R, Schluesener HJ. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med. 2013;17(12):1566-1576.

Wang S, Yang H, Yu L, et al. Oridonin attenuates Abeta1-42-induced neuroinflammation and inhibits NF-kappaB pathway. PloS One. 2014;9(8),e104745.

Wang LX, Sun Y, Chen C, et al. Effects and mechanism of oridonin on pulmonary hypertension induced by chronic hypoxia-hypercapnia in rats. Chin Med J. 2009;122(12):1380-1387.

Wang MY, Lin C, Zhang TM. [Cytokinetic effects of oridonin on leukemia L1210 cells]. Zhongguo Yaoli Xuebao. 1985;6(3):195-198.

Liu JJ, Huang RW, Lin DJ, et al. Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J Int Med Res. 2004;32(6):617-625.

Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res. 2004;6(2):127-138.

Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S, Ikejima T. Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci. 2004;96(2):155-163.

Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Bcl-2 up-regulation and P-p53 down-regulation account for the low sensitivity of murine L929 fibrosarcoma cells to oridonin-induced apoptosis. Biol Pharm Bull. 2005;28(11):2068-2074.

Zhang JF, Liu JJ, Liu PQ, Lin DJ, Li XD, Chen GH. Oridonin inhibits cell growth by induction of apoptosis on human hepatocelluar carcinoma BEL-7402 cells. Hepatol Res. 2006;35(2):104-110.

Liu YQ, You S, Zhang CL, Tashiro S, Onodera S, Ikejima T. Oridonin enhances phagocytosis of UV-irradiated apoptotic U937 cells. Biol Pharm Bull. 2005;28(3):461-467.

Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull. 2007;30(5):859-864.

Qi X, Zhang D, Xu X, et al. Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int J Nanomed. 2012;7:1793-1804.

Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci. 2008;107(4):370-379.

Zeng R, Chen Y, Zhao S, Cui GH. Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol Sin. 2012;33(1):91-100.

Cao Y, Wei W, Zhang N, et al. Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-kappaB signaling. BMC Canc. 2015;15,e248.

Sun Y, Jiang X, Lu Y, et al. Oridonin prevents epithelial-mesenchymal transition and TGF-beta1-induced epithelial-mesenchymal transition by inhibiting TGF-beta1/Smad2/3 in osteosarcoma. Chem Biol Interact. 2018;296:57-64.

Liu QQ, Chen K, Ye Q, Jiang XH, Sun YW. Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/beta-catenin signaling pathway. Canc Cell Int. 2016;16,e57.

Yao Z, Xie F, Li M, et al. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis. 2017;8(2),e2633.

Xu W, Sun J, Zhang TT, et al. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol Sin. 2006;27(12):1642-1646.

Xu J, Yang J, Ran Q, et al. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg Med Chem Lett. 2008;18(16):4741-4744.

Liu W, Zhao B, Li YC, Liu HM. NMR spectra and structures of oridonin derivatives complexes with beta-cyclodextrin. Magn Reson Chem : MRC. 2011;49(9):611-615.

Wang L, Li D, Xu S, et al. The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents. Eur J Med Chem. 2012;52:242-250.

Xu S, Yao H, Luo S, et al. A novel potent anticancer compound optimized from a natural oridonin scaffold induces apoptosis and cell cycle arrest through the mitochondrial pathway. J Med Chem. 2017;60(4):1449-1468.

Ma YC, Ke Y, Zi X, et al. Induction of the mitochondria-mediated apoptosis in human esophageal cancer cells by DS2, a newly synthetic diterpenoid analog, is regulated by Bax and caused by generation of reactive oxygen species. Oncotarget. 2016;7(52):86211-86224.

Wang SQ, Wang C, Chang LM, et al. Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway. Oncotarget. 2016;7(45):72990-73002.

Wang SQ, Wang C, Wang JW, et al. Geridonin, a novel derivative of oridonin, inhibits proliferation of MGC 803 cells both in vitro and in vivo through elevating the intracellular ROS. J Pharm Pharmacol. 2017;69(2):213-221.

Li D, Wang L, Cai H, Zhang Y, Xu J. Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents. Molecules. 2012;17(6):7556-7568.

Li D, Cai H, Jiang B, et al. Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells. Eur J Med Chem. 2013;59:322-328.

Li D, Xu S, Cai H, et al. Enmein-type diterpenoid analogs from natural kaurene-type oridonin: synthesis and their antitumor biological evaluation. Eur J Med Chem. 2013;64:215-221.

Li H, Mu J, Sun J, et al. Hydrogen sulfide releasing oridonin derivatives induce apoptosis through extrinsic and intrinsic pathways. Eur J Med Chem. 2020;187,e111978.

Li D, Han T, Tian K, et al. Novel nitric oxide-releasing spirolactone-type diterpenoid derivatives with in vitro synergistic anticancer activity as apoptosis inducer. Bioorg Med Chem Lett. 2016;26(17):4191-4196.

Li D, Hu X, Han T, et al. NO-releasing enmein-type diterpenoid derivatives with selective antiproliferative activity and effects on apoptosis-related proteins. Molecules. 2016;21(9),e1193.

Xu S, Wang G, Lin Y, et al. Novel anticancer oridonin derivatives possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation and nitric oxide release studies. Bioorg Med Chem Lett. 2016;26(12):2795-2800.

Xu S, Yao H, Hu M, et al. 6,7-Seco-ent-Kauranoids derived from oridonin as potential anticancer agents. J Nat Prod. 2017;80(9):2391-2398.

Xu S, Li D, Pei L, et al. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorg Med Chem Lett. 2014;24(13):2811-2814.

Hu X, Bai Z, Qiao J, et al. Effective enmein-type mimics of clinical candidate HAO472: design, synthesis and biological evaluation. Eur J Med Chem. 2019;171:169-179.

Li H, Gao X, Huang X, et al. Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: design, synthesis and antiproliferative properties. Eur J Med Chem. 2019;178:446-457.

Ding C, Zhang Y, Chen H, et al. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J Med Chem. 2013;56(12):5048-5058.

Ding C, Wang L, Chen H, et al. ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Org Biomol Chem. 2014;12(42):8442-8452.

Ding C, Zhang Y, Chen H, et al. Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Org Lett. 2013;15(14):3718-3721.

Chen W, Zhou J, Wu K, et al. Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. Oncotarget. 2016;7(35):56842-56854.

Zhou J, Yun E-J, Chen W, et al. Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. Cell Death Dis. 2017;8(3),e2701.

Ding C, Zhang Y, Chen H, et al. Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J Med Chem. 2013;56(21):8814-8825.

Li D, Wang H, Ding Y, et al. Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis. Canc Lett. 2018;424:97-108.

Ding Y, Li D, Ding C, et al. Regio- and stereospecific synthesis of oridonin D-ring aziridinated analogues for the treatment of triple-negative breast cancer via mediated irreversible covalent warheads. J Med Chem. 2018;61(7):2737-2752.

Bohanon FJ, Wang X, Graham BM, et al. Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis. J Surg Res. 2015;199(2):441-449.

Bohanon FJ, Wang X, Graham BM, et al. Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells. Mol Cell Biochem. 2015;410(1–2):293-300.

Cummins CB, Wang X, Xu J, et al. Antifibrosis effect of novel oridonin analog CYD0618 via suppression of the NF-kappaB pathway. J Surg Res. 2018;232:283-292.

Shen X, Zhao L, Chen P, et al. A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3. J Biol Chem. 2019;294(46):17471-17486.

Li Y, Wang Y, Wang S, Gao Y, Zhang X, Lu C. Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells. Med Oncol. 2015;32(1),e365.

Shen Q-K, Chen Z-A, Zhang H-J, et al. Design and synthesis of novel oridonin analogues as potent anticancer agents. J Enzym Inhib Med Chem. 2018;33(1):324-333.

Shen Q-K, Deng H, Wang S-B, Tian Y-S, Quan Z-S. Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: a novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway. Eur J Med Chem. 2019;173:15-31.

Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12(1):9-18.

Bu HQ, Luo J, Chen H, et al. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. Int J Oncol. 2012;41(3):949-958.

Liu D-L, Bu H-Q, Jin H-M, Zhao J-F, Li Y, Huang H. Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway. Mol Med Rep. 2014;10(6):3027-3034.

Zhang H-P, Li G-Q, Guo W-Z, et al. Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway. Oncotarget. 2017;8(63):106833-106843.

Shi M, Ren X, Wang X, et al. A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells. Int J Oncol. 2016;48(2):734-746.

Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets. 2006;6(1):65-75.

Zhang W, Lu Y, Zhen T, et al. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia. Front Med. 2019;13(3):388-397.

Spirin P, Lebedev T, Orlova N, et al. Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors. Oncotarget. 2017;8(34):56991-57002.

Qing K, Jin Z, Fu W, et al. Synergistic effect of oridonin and a PI3K/mTOR inhibitor on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma. J Hematol Oncol. 2016;9(1),e72.

Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Canc Biol Ther. 2012;13(13):1244-1254.

Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453-R462.

Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-591.

Sadaf N, Kumar N, Ali M, Ali V, Bimal S, Haque R. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells. Life Sci. 2018;205:9-17.

Li JX, Shen YQ, Cai BZ, et al. Arsenic trioxide induces the apoptosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation. Mol Biol Rep. 2010;37(3):1569-1576.

Chen G, Wang K, Yang BY, Tang B, Chen JX, Hua ZC. Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol. 2012;40(1):139-147.

Du Y, Villeneuve NF, Wang XJ, et al. Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ Health Perspect. 2008;116(9):1154-1161.

Cao S, Xia M, Mao Y, et al. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway. Int J Oncol. 2016;49(5):2075-2087.

Park H, Jeong YJ, Han NK, Kim JS, Lee HJ. Oridonin enhances radiation-induced cell death by promoting DNA damage in non-small cell lung cancer cells. Int J Mol Sci. 2018;19(8),e2378.

Sun Z, Han Q, Duan L, Yuan Q, Wang H. Oridonin increases anticancer effects of lentinan in HepG2 human hepatoblastoma cells. Oncol Lett. 2018;15(2):1999-2005.

Dong X, Liu F, Li M. Inhibition of nuclear factor κB transcription activity drives a synergistic effect of cisplatin and oridonin on HepG2 human hepatocellular carcinoma cells. Anti Canc Drugs. 2016;27(4):286-299.

Tiwari RV, Parajuli P, Sylvester PW. gamma-Tocotrienol-induced autophagy in malignant mammary cancer cells. Exp Biol Med. 2014;239(1):33-44.

Tiwari RV, Parajuli P, Sylvester PW. Synergistic anticancer effects of combined gamma-tocotrienol and oridonin treatment is associated with the induction of autophagy. Mol Cell Biochem. 2015;408(1–2):123-137.

Wang XH, Zhang SF, Bao JT, Liu FY. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins. Tumour Biol. 2017;39(6),e1010428317701638.

Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updates. 2010;13(4–5):109-118.

Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Canc Lett. 2014;347(2):159-166.

Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43(8):723-737.

Efferth T, Davey M, Olbrich A, Rucker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis. 2002;28(2):160-168.

He Z, Xiao X, Li S, et al. Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells. Oncol Lett. 2017;14(2):2499-2504.

Yuan R, Hou Y, Sun W, et al. Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci. 2017;1401(1):19-27.

Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Canc. 2002;2(4):277-288.

Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers. 2019;11(1),e119.

Ma S, Tan W, Du B, et al. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Mol Med Rep. 2016;13(4):3342-3348.

Zhang Y, Wang L, Zi Y, Zhang L, Guo Y, Huang Y. Oridonin effectively reverses the drug resistance of cisplatin involving induction of cell apoptosis and inhibition of MMP expression in human acute myeloid leukemia cells. Saudi J Biol Sci. 2017;24(3):678-686.

Zhao Y, Xia H. Oridonin elevates sensitivity of ovarian carcinoma cells to cisplatin via suppressing cisplatin-mediated autophagy. Life Sci. 2019;233,e116709.

Chen S, Cooper M, Jones M, et al. Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells: sensitivity of ovarian cancer cells to phyto-active chemicals. Cell Biol Toxicol. 2011;27(2):133-147.

Weng H, Huang H, Dong B, Zhao P, Zhou H, Qu L. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Canc Res. 2014;74(16):4409-4419.

Geserick P, Wang J, Schilling R, et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 2015;6,e1884.

Zheng W, Zhou CY, Zhu XQ, et al. Oridonin enhances the cytotoxicity of 5-FU in renal carcinoma cells by inducting necroptotic death. Biomed Pharmacother. 2018;106:175-182.

Zhang D, Zhou Q, Huang D, et al. ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells. Biochem Biophys Res Commun. 2019;513(3):594-601.

Wang B, Shen C, Li Y, et al. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling. OncoTargets Ther. 2019;12:5751-5765.

Xiao X, He Z, Cao W, et al. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol. 2016;48(6):2608-2618.

Kadioglu O, Saeed M, Kuete V, Greten HJ, Efferth T. Oridonin targets multiple drug-resistant tumor cells as determined by in silico and in vitro analyses. Front Pharmacol. 2018;9,e355.

Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Canc Cell. 2002;2(2):117-125.

Huang H, Weng H, Dong B, Zhao P, Zhou H, Qu L. Oridonin triggers chaperon-mediated proteasomal degradation of BCR-ABL in leukemia. Sci Rep. 2017;7,e41525.

Shan QQ, Guo Y, Gong YP, Lin J, Wang YS. Anti-Leukemia effect and mechanism of oridonin on imatinib-sensitive and imatinib-resistant K562 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25(5):1378-1383.

Huang H-L, Weng H-Y, Wang L-Q, et al. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Canc Therapeut. 2012;11(5):1155-1165.